In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Wave Life Sciences (WVE), with a price target of $10.00. The company’s shares closed last Wednesday at $6.73, close to its 52-week low of $4.82.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 15.3% and a 49.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Global Blood Therapeutics.
Currently, the analyst consensus on Wave Life Sciences is a Moderate Buy with an average price target of $9.33, which is a 38.4% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $8.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.98 and a one-year low of $4.82. Currently, Wave Life Sciences has an average volume of 975.1K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of WVE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
